OTCMKTS:AFFY Affymax (AFFY) Stock Price, News & Analysis → Emergency: Biden's $20 Trillion Mistake Could Cost YOU! (From GoldenCrest Metals) (Ad) Free AFFY Stock Alerts $0.0007 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$0.0007▼$0.000750-Day Range N/A52-Week Range$0.00▼$0.04VolumeN/AAverage Volume23,949 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsShort InterestStock AnalysisChartFinancialsShort Interest Get Affymax alerts: Email Address Ad GoldenCrest MetalsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.Learn More Now About Affymax Stock (OTCMKTS:AFFY)Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.Read More AFFY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AFFY Stock News HeadlinesApril 4, 2024 | finance.yahoo.comFull Glass Wine Co. Secures $14 Million Funding; Acquires Leading DTC Wine Subscription Brand, Bright CellarsFebruary 27, 2024 | finance.yahoo.comNested Therapeutics Strengthens Board of Directors with Appointment of New Chair and DirectorsApril 24, 2024 | GoldenCrest Metals (Ad)Emergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.February 23, 2024 | benzinga.comAffymax Stock (OTC:AFFY), Short Interest ReportSeptember 25, 2023 | finance.yahoo.comJasper Therapeutics Appoints Herb Cross as Chief Financial OfficerSeptember 18, 2023 | markets.businessinsider.comAnaptysBio Announces Appointment of John Orwin as Chairman of the Board of DirectorsJune 7, 2023 | thestreet.com4 Biotech Stocks Under $5 to WatchMay 15, 2023 | thestreet.com10 Biotech Stocks on Clinical Trials WatchApril 24, 2024 | GoldenCrest Metals (Ad)Emergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.January 19, 2023 | bizjournals.comWhy a UCSF vice chancellor is returning to the biotech industryJanuary 18, 2023 | marketwatch.comHinge Bio Expands Senior Management Team to Drive GEM-DIMER(TM) Programs to Clinical DevelopmentJanuary 18, 2023 | nz.finance.yahoo.comHinge Bio Expands Senior Management Team to Drive GEM-DIMER™ Programs to Clinical DevelopmentSeptember 14, 2022 | finanznachrichten.deTurn Biotechnologies, Inc.: Turn Biotechnologies launches eTurna delivery platform designed specifically to enable nucleic acid therapeuticsAugust 28, 2022 | reuters.comAFFY.PK - Affymax, Inc. | Stock Price & Latest News | ReutersAugust 25, 2022 | finance.yahoo.comFrontier Medicines Announces the Appointment of Seasoned Legal Executive Mark Dizon, J.D., as General CounselAugust 3, 2022 | investing.comEsso Thailand PCL F (ESSOf)August 3, 2022 | investing.comDialog Group Bhd (DIAL)July 30, 2022 | investing.comDPS Resources Bhd (DPSS)April 27, 2022 | marketwatch.comRenal Disease Treatment Market Size with New Growth Prospect By Top Key Players | Impact of COVID-19 PandemicMarch 27, 2022 | marketwatch.comRenal Disease Treatment Market Scope with New Growth Prospect By Top Key Players | Impact of COVID-19 PandemicSeptember 2, 2021 | ca.finance.yahoo.comArcutis Announces Appointment of Keith Leonard to Board of DirectorsSee More Headlines Receive AFFY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Affymax and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolOTCMKTS:AFFY CUSIP00826A10 CIK1158223 Webwww.affymax.com Phone(650) 812-8700Fax650-424-0832Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta5.90 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Mark G. Thompson (Age 62)CFO & Secretary Comp: $97.49kMr. Jonathan M. Couchman (Age 54)CEO, President & Director Dr. Tracy J. Dunn Ph.D. (Age 61)J.D., Vice President of Intellectual Property & Legal Affairs Key CompetitorsAbliva AB (publ)OTCMKTS:NEVPFAcusphereOTCMKTS:ACUSAddex TherapeuticsOTCMKTS:ADDXFAeolus PharmaceuticalsOTCMKTS:AOLSAlseres PharmaceuticalsOTCMKTS:ALSEView All Competitors AFFY Stock Analysis - Frequently Asked Questions How have AFFY shares performed in 2024? Affymax's stock was trading at $0.0006 at the beginning of 2024. Since then, AFFY stock has increased by 16.7% and is now trading at $0.0007. View the best growth stocks for 2024 here. What other stocks do shareholders of Affymax own? Based on aggregate information from My MarketBeat watchlists, some companies that other Affymax investors own include Golden Peak Minerals Inc.. (GRM), (MCPIQ) (MCPIQ), Bank of America (BAC), Boeing (BA), American Express (AXP), Aurinia Pharmaceuticals (AUPH), Actinium Pharmaceuticals (ATNM), Advanced Micro Devices (AMD), Alnylam Pharmaceuticals (ALNY) and Achaogen (AKAO). How do I buy shares of Affymax? Shares of AFFY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:AFFY) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe Greatest Bull Market in Crypto History…Weiss RatingsNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affymax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.